DRUG COST ANALYSIS ON NATIONAL HEALTH INSURANCE ERA IN HEALTH SUPPORT FACILITIES
Journal Title: Asian Journal of Pharamceutical and Clinical Research - Year 2017, Vol 10, Issue 2
Abstract
Objective: In national health insurance (JKN) era, pharmacy can play roles in the form of behind refer pharmacies, or networking pharmacy and clinic pharmacy pratama. Behind refer pharmacies drug cost can be claimed directly to BPJS, meanwhile for the other type of pharmacy have to negotiation first with the primary health care. Drug cost variations in the JKN era affect the profitability of the business pharmacies. This research aims to the drug percentage charges against capitation and variety of drug costs.Methods: This research is analytic observational cross-sectional. This research uses secondary data from a JKN prescription patient. This research was conducted on 6 affiliated pharmacies, 6 networking pharmacies, and 7 clinical pharmacy pratama in DIY. The sampling in this research is by purposive with 8.430 prescriptions. Data drug costs JKN era was analyzed by descriptive statistics and comparative test (Kruskal Wallis test).Results: The result showed that average percentage of drug costs for capitation fee in the networking pharmacy is 13.58% and primary health care is 15.91%. Pharmacy in JKN era has drug cost variations (p=0.000). Drug cost in JKN era depends on the pattern of play roles with the health facilities and BPJS. The average percentage of drug costs against capitation health facilities in networking pharmacy is lower than clinical pharmacy pratama.Conclusions: Drug costs in an era of JKN depending on the pattern of cooperation with health facilities pharmacies and BPJS. The average percentage of the cost of drugs to the pharmacy capitation health facilities in networking lower than clinic pharmacy pratama. Differences in drug costs JKN era influenced by the long days of drug administration, the number of prescription sheets, margin.Keywords: Drug cost analysis, National health insurance (JKN), Pharmacy, Primary health care, Capitation.
Authors and Affiliations
Satibi Satibi, Dewa Ayu Putu Satrya Dewi, Atika Dalili Akhmad, Novita Kaswindiarti, Dyah Ayu Puspandari
Keywords
Related Articles
- EP ID EP605414
- DOI 10.22159/ajpcr.2017.v10i2.14577
- Views 91
- Downloads 0
CAROTID ARTERY INTIMA-MEDIA THICKNESS AND 10-YEAR RISK OF HEART DISEASE IN DIABETIC PATIENTS: A COMPARATIVE STUDY
Objective: The aim of the present study was to assess the factors affecting carotid artery intima-media thickness (CIMT) and 10-year risk of heart disease in diabetic patients classified according to CIMT. Methods: This...
EVALUATION OF GAS CHROMATOGRAPHY-MASS SPECTROMETRY AND CYTOTOXICITY OF ETHANOLIC LEAF EXTRACT OF ACACIA CAESIA (L.) WILLD. AGAINST HELA CELL LINE
Objective: The objective of this study is to analyze the bioactive compounds of the ethanolic leaf extract of Acacia caesia using gas chromatography-mass spectrometry (GC-MS) method and also screen the in vitro cytotoxic...
EFFECT OF VITAMIN D SUPPLEMENTATION ON INSULIN SENSITIVITY AND ANDROGEN LEVEL IN VITAMIN D-DEFICIENT POLYCYSTIC OVARY SYNDROME PATIENTS
Objectives: There is limited evidence that giving Vitamin D supplementation had a beneficial effect on insulin resistance and dysfunction of the menstrual cycle in females with polycystic ovary syndrome (PCOS). Thus, the...
DESIGN, SYNTHESIS, MOLECULAR DOCKING, AND BIOLOGICAL EVALUATION OF PYRAZOLE 1-CARBOTHIAMIDE INCORPORATED ISOXAZOLE DERIVATIVES
Objectives: Novel isoxazole incorporated pyrazole carbothiamide 5 (a-r) was designed and synthesized, docked and evaluated for anticancer activity Michigan Cancer Foundation-7 (MCF-7), and breast cancer cell lines. Mate...
METHOD DEVELOPMENT AND VALIDATION OF UV-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF ASSAY OF SUGAMMADEX SODIUM, APREMILAST, RIOCIGUAT AND VORAPAXAR SULFATE DRUGS IN API FORM.
Objective: The objective of the present work is to develop a simple, efficient and reproducible spectrophotometric method for the quantitative estimation of Sugammadex Sodium, Apremilast, Riociguat and Vorapaxar sulfate...